Lv35
310 积分 2026-01-12 加入
Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial
4天前
已完结
Comparison of neoadjuvant chemoimmunotherapy with or without concurrent radiotherapy for locally advanced resectable esophageal squamous cell carcinoma: a multicenter retrospective study
8天前
已完结
Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)
8天前
已完结
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
8天前
已完结
Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety
10天前
已完结
Synthetic Approaches to the New Drugs Approved During 2022
11天前
已完结
Pharmacokinetics of Eltrombopag in Healthy Chinese Subjects and Effect of Sex and Genetic Polymorphism on its Pharmacokinetic and Pharmacodynamic Variability
13天前
已完结
Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study
17天前
已完结
Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study
17天前
已完结
Pathologic complete response after neoadjuvant immunochemotherapy: Persistent recurrence risk highlights the need for stratified management
20天前
已完结
皖公网安备34019202002308
